Please select the option that best describes you:
When treating a patient with multiple myeloma with bortezomib, how do you decide between subcutaneous vs intravenous dosing?
Subq has been shown to have lower risk of neuropathy. Is there any reason to use weekly IV still?
Answer from: Medical Oncologist at Academic Institution
Due to the markedly increased risk of of peripheral neuropathy, the standard of care worldwide is to utilize subcutaneous bortezomib. There really is no medical indication to prefer IV over SQ. The issue of weekly versus biweekly bortezomib is controversial. The FDA indication is for biweekly ...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
I never use bortezomib iv
Answer from: Medical Oncologist at Community Practice
The only time I would use IV Velcade is when pt has severe skin reaction to sc.